<DOC>
	<DOC>NCT01229839</DOC>
	<brief_summary>TACE is considered the standard treatment for unresectable HCC on the basis of the fact that there are no alternative to curative procedures.But the optimal combined regimen is still unclear. One of the controversy is do the protocol should contain lipiodo and how to executer. The investigators hypothesize that TACE without mixing the chemotherapy with lipiodol is not unacceptably worse than TACE mixing the chemotherapy with lipiodol.</brief_summary>
	<brief_title>Chemoembolization With or Without Mixing the Chemotherapy With Lipiodol for Unresectable HCC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Ethiodized Oil</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<criteria>Eligibility criteria: Adults patients with a diagnosis of HCC which is not amenable to surgical resection ,local ablative therapy and any other cured treatment. Patients must have at least one tumor lesion that can be accurately measured according to EASL criteria. And the lesion has not been previously treated with TACE, surgery, radiation therapy, radiofrequency ablation, percutaneous ethanol or acetic acid injection, or cryoablation. No serious concurrent medical illness Unresectable BCLC stage AB disease No cirrhosis or cirrhotic status of ChildPugh class A No significant renal impairment (creatinine clearance &lt; 30 mL/minute) or patients on dialysis No current infections requiring antibiotic therapy Not on anticoagulation or suffering from a known bleeding disorder No unstable coronary artery disease or recent MI The following laboratory parameters: Platelet count ≥ 60,000/µL Hemoglobin ≥ 8.5 g/dL Total bilirubin ≤ 1.5 mg/dL Serum albumin ≥ 35 g/L ASL and AST ≤ 5 x upper limit of normal Serum creatinine ≤ 1.5 x upper limit of normal INR ≤ 1.5 or PT/APTT within normal limits Absolute neutrophil count (ANC) &gt;1,500/mm3 Ability to understand the protocol and to agree to and sign a written informed consent document Known history of HIV History of organ allograft Pregnant or breastfeeding patients Known or suspected allergy to the investigational agents or any agent given in association with this trial. Cardiac ventricular arrhythmias requiring antiarrhythmic therapy Evidence of bleeding diathesis. Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry. Any other hemorrhage/bleeding event &gt; CTCAE Grade 3 within 4 weeks of first dose of study drug Serious nonhealing wound, ulcer, or bone fracture Known central nervous system tumors including metastatic brain disease severe Arterioportal Shunts or Arteriavein Shunts</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Carcinoma,Hepatocellular</keyword>
	<keyword>Liver Neoplasms</keyword>
	<keyword>Therapeutic</keyword>
	<keyword>Chemoembolization,</keyword>
	<keyword>TACE</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Iodized Oil/administration &amp; dosage</keyword>
	<keyword>polyvinyl alcohol</keyword>
	<keyword>Humans</keyword>
</DOC>